Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- This market has had an incredible run over the past six years, Jim Cramer told his Mad Money viewers Wednesday, and there's no shortage of ideas for how to take stocks even higher.
That was Cramer's takeaway from today's Delivering Alpha conference presented by CNBC, as the very best investors the world has to offer made presentations on their favorite stocks. Many of these activists and fund managers had some unique views that made Cramer take notice.
Take a stock like Macy's(M) - Get Report, a retailer that has not been doing very well despite a growing job market, falling oil prices and a strong dollar that is keeping investment dollars here at home. Using a traditional earnings per share model, investors might steer clear of Macy's, but at Delivering Alpha, the case was made that the company's real estate alone could unlock a ton of value, sending shares from $72 to $125. That idea alone sent Macy's shares up 8%.
Then there's Ethan Allen (ETH) - Get Report. another struggling retailer that sits upon exceptional real estate that could be worth a bundle. Or how about McDonald's(MCD) - Get Report, a company that activists Nelson Peltz and Bill Ackman both say is more than fixable.
What's Next in Biotech?
With the news that Celgene(CELG) - Get Report, one of Cramer's favorite biotech stocks, is buying Receptos (RCPT) , another of Cramer's biotech faves, for $232 a share, it's only natural to ask, "What's next?"
Cramer first commended Celgene for having the foresight to buy Receptos, and it's pipeline in a drug called Ozanimod, which could potentially treat overeating from multiple sclerosis to autoimmune diseases, Crohn's and a host of other gastrointestinal ailments. Receptos has been a long-time Cramer fav and is one of the highest gaining stocks ever recommended on Mad Money.
As for what's next, Cramer said many of the biotechs are trading too high to recommend at the moment, but there's no doubt in his mind that more deals like Receptos will be coming soon in this red-hot group.
Executive Decision: Ken Powell
For his "Executive Decision" segment, Cramer sat down with Ken Powell, chairman and CEO of General Mills(GIS) - Get Report, the cereal and snack maker undergoing a transformation as consumer tastes evolve.
Powell said that consumer tastes are indeed changing, and rapidly, which is why General Mills is innovating faster than ever before with a new "consumer first" strategy aimed at giving people what they've been asking for.
General Mills has already committed to making its venerable Cheerios, Lucky Charms and Chex cereals gluten free and is working hard to remove artificial colors and flavors with natural alternatives.
Another big opportunity, Powell noted, is snacks, a category which is seeing exploding growth as Americans are eating few meals and snacking on the go instead.
General Mills is also partnering with schools to meet new guidelines for breakfasts and lunches that include healthier alternatives with less sugars and processing.
Finally, Powell noted that they're very excited to debut yogurt in China, and so far they're off to a great start.
Executive Decision: Dan Leever
In his second "Executive Decision" segment, Cramer sat down with Dan Leever, CEO of Platform Specialty Products(PAH) - Get Report, a specialty chemical acquirer with a stock that's up 11.9% so far in 2015.
Leever explained that Platform Specialty is interested in acquiring high quality, high cash flow businesses and putting them all under the Platform umbrella. Currently, Platform consists of about 50% agricultural chemicals and the rest specialty chemicals, although Leever noted that his aim is to be more broadly diversified over time.
When asked about finding assets to acquire, Leever said there are hundreds of billions of dollars worth of assets that fit their model, from cleaning products to oil field services and even flavors and fragrances.
Despite being up against some big, entrenched competition, Cramer said that Platform Specialty has great long-term prospects.
Chart Week: Carolyn Boroden
As "Chart Week" on "Mad Money" continues, Cramer welcomed Carolyn Boroden, the "Fibonacci Queen," to teach viewers about the concept of price extensions as it relates to her analysis of stocks and the markets.
Boroden explained that price extension help her determine support and resistance levels in her charting. The concept is to measure the move in a stock or index, from top to bottom or bottom to top, then reverse it and multiply by 1.272 to predict the next move higher or lower.
Looking at a daily chart of the Russell 2000 ETF, Boroden looked at the top to bottom move last October, extended that move to 1.272, and accurately predicted that index's next move higher. The same pattern worked again during the January and April pullbacks as well.
Finally, Boroden looked at Exxon Mobil(XOM) - Get Report, noting multiple price relationships and extensions converging at current levels. She said if the stock can hold above these levels, she'd be confident in calling a bottom in the stock.
This article is being updated. Please refresh for the latest version.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.